Mepartricin

Mepartricin
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • (19E,21E,23Z,25Z,27E,29E,31E)-Methyl 34-((2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-1,3,5,7,9,13,37-heptahydroxy-17-(5-hydroxy-7-[4-(methylamino)phenyl]-7-oxoheptan-2-yl)-18-methyl-11,15-dioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.057.786
Edit this at Wikidata
Chemical and physical data
FormulaC60H88N2O19
Molar mass1141.359 g·mol−1
3D model (JSmol)
SMILES
  • CNc1ccc(cc1)C(=O)CC(O)CCC(C)C3OC(=O)CC(O)CC(=O)CC(O)CC(O)CC(O)CC(O)CC4(O)CC(O)C(C(=O)OC)C(CC(O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)/C=C/C=C/C=C/C=C\C=C/C=C/C=C/C3C)O4
InChI
  • InChI=1S/C60H88N2O19/c1-36-18-16-14-12-10-8-6-7-9-11-13-15-17-19-48(79-59-56(74)54(61)55(73)38(3)78-59)33-51-53(58(75)77-5)50(71)35-60(76,81-51)34-47(69)30-45(67)28-43(65)26-42(64)27-44(66)29-46(68)32-52(72)80-57(36)37(2)20-25-41(63)31-49(70)39-21-23-40(62-4)24-22-39/h6-19,21-24,36-38,41-43,45-48,50-51,53-57,59,62-65,67-69,71,73-74,76H,20,25-35,61H2,1-5H3/b7-6-,10-8-,11-9+,14-12+,15-13+,18-16+,19-17+/t36?,37?,38-,41?,42?,43?,45?,46?,47?,48?,50?,51?,53?,54+,55-,56+,57?,59+,60?/m1/s1 checkY
  • Key:GVEVTKSEPQUIJA-PLDHRHJXSA-N checkY
  (verify)

Mepartricin is a macrolide polyene compound that is useful for urethra, prostate, and bladder function. It has been studied for use in treating chronic pelvic pain syndrome and benign prostatic hyperplasia.[1][2]

Pharmacodynamics

Mepartricin is estrogen reabsorption inhibitor that may interfere with the reabsorption of estrogens in the gut leading to increased fecal estrogen excretion. It reduces 17β-estradiol concentration in enterohepatic circulation and decreases estrogen levels in the prostate. The effect of mepartricin on the reabsorption of estrogens was evaluated in studies in vitro and in vivo.

Mepartricin significantly improves pelvic pain and quality of life compared with the results in placebo group after two months of treatment.[1] Regarding to the theory that hormonal disorders could promote prostatic inflammation,[3] mepartricin, that can lower estrogen levels in prostate, is effective drug in the treatment of patients with chronic pelvic pain syndrome [4] and is referred in 2015 World Journal Pharmacology Updates on therapies for chronic prostatitis/chronic pelvic pain syndrome.

References

  1. 1 2 De Rose AF, Gallo F, Giglio M, Carmignani G (January 2004). "Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial". Urology. 63 (1): 13–6. doi:10.1016/j.urology.2003.08.006. PMID 14751338.
  2. ↑ Erickson BA, Schaeffer AJ, Van Le B (2008). "Chronic prostatitis". Clin Evid (Online). 2008. PMC 2907954. PMID 19450305.
  3. ↑ Fan S, Hao ZY, Zhang L, Chen XG, Zhou J, Zang YF, Tai S, Liang CZ (2014). "Increased chromogranin A and neuron-specific enolase in rats with chronic nonbacterial prostatitis induced by 17-beta estradiol combined with castration". Int J Clin Exp Pathol. 7 (7): 3992–9. PMC 4129011. PMID 25120776.
  4. ↑ Cohen JM, Fagin AP, Hariton E, Niska JR, Pierce MW, Kuriyama A, Whelan JS, Jackson JL, Dimitrakoff JD (2012). "Therapeutic Intervention for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/ CPPS): A Systematic Review and Meta-Analysis". PLOS ONE. 7 (8): e41941. Bibcode:2012PLoSO...741941C. doi:10.1371/journal.pone.0041941. PMC 3411608. PMID 22870266.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.